Short Interest in Eterna Therapeutics Inc. (NASDAQ:ERNA) Declines By 39.6%

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the target of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 186,600 shares, a decrease of 39.6% from the January 31st total of 309,100 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average daily volume of 10,530,000 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Trading of Eterna Therapeutics

A hedge fund recently raised its stake in Eterna Therapeutics stock. Geode Capital Management LLC increased its position in shares of Eterna Therapeutics Inc. (NASDAQ:ERNA) by 1,159.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 257,310 shares of the company’s stock after acquiring an additional 236,875 shares during the quarter. Geode Capital Management LLC owned approximately 4.76% of Eterna Therapeutics worth $76,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 70.55% of the company’s stock.

Eterna Therapeutics Trading Down 8.2 %

Shares of ERNA stock traded down $0.02 during trading hours on Monday, hitting $0.28. The company’s stock had a trading volume of 403,144 shares, compared to its average volume of 15,956,578. The business has a fifty day moving average of $0.35 and a 200-day moving average of $0.80. The stock has a market cap of $1.51 million, a price-to-earnings ratio of -0.03 and a beta of 4.29. Eterna Therapeutics has a twelve month low of $0.22 and a twelve month high of $2.63.

About Eterna Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.